Role of Nanocarriers in Management of Non-Hodgkin Lymphoma is a pivotal resource that explores the transformative impact of nanotechnology on the diagnosis, treatment, and management of non-Hodgkin’s lymphoma (NHL). This comprehensive guide bridges the gap between innovative research and clinical application, focusing on advancements in polymeric nanoparticles, lipid carriers, carbon nanotubes, and immunotherapy approaches. The book provides an in-depth analysis of current technologies and future directions in integrating nanocarriers into NHL management. Each chapter offers evidence-based insights and mechanisms of action, emphasizing the synergy between immunotherapy, precision medicine, and nanotechnology. This resource benefits its academic audience by equipping healthcare professionals with innovative strategies to improve treatment outcomes and inspiring researchers to explore novel therapeutic pathways. By fostering interdisciplinary collaboration among oncologists, pharmaceutical developers, and nanotechnology experts, the book ultimately guides future research to enhance patient care in the rapidly evolving field of non-Hodgkin’s lymphoma management.
1. Chapter 1 Introduction to non-Hodgkin’s disease and conventional therapies - p. 1 2. Chapter 2 Immune checkpoint inhibitors in the management of Non-Hodgkin’s Lymphoma: An emerging paradigm in reprogramming antitumor immunity - p. 33 3. Chapter 3 Exploring polymeric nanoparticles in Non-Hodgkin’s Lymphoma management - p. 67 4. Chapter 4 Magnetic nanoparticles in Non-Hodgkin’s Lymphoma therapy: Advancements and future directions - p. 87 5. Chapter 5 Leveraging nanostructured lipid carriers (NLCs) in Non-Hodgkin’s Lymphoma management - p. 113 6. Chapter 6 Breakthrough in antibody–drug conjugates for Non-Hodgkin Lymphoma management - p. 135 7. Chapter 7 Targeted Non-Hodgkin’s Lymphoma management with carbon nanotubes - p. 161 8. Chapter 8 Advancement in Non-Hodgkin’s Lymphoma management using exosomes - p. 187 9. Chapter 9 Immunological and molecular insights into vaccine-based and immunotherapeutic strategies for Non-Hodgkin’s Lymphoma - p. 205 10. Chapter 10 Immunotherapy and radioimmunotherapy approaches for Non-Hodgkin’s Lymphoma management - p. 227 11. Chapter 11 Innovative mRNA-based therapeutic strategies for Non-Hodgkin’s Lymphoma management - p. 265 12. Chapter 12 Monoclonal antibody and CAR T-cell therapy: A novel avenue in Non-Hodgkin’s Lymphoma management - p. 291 13. Chapter 13 Combination of nanocarrier with chemotherapy for Non-Hodgkin’s Lymphoma management - p. 305 14. Chapter 14 Patient care in Non-Hodgkin’s Lymphoma management - p. 329 15. Chapter 15 Regulatory challenges and approvals for nanocarrier-based therapies - p. 349 16. Index - p. 369
Role of Nanocarriers in Management of Non-Hodgkin Lymphoma is a pivotal resource that explores the transformative impact of nanotechnology on the diagnosis, treatment, and management of non-Hodgkin’s lymphoma (NHL). This comprehensive guide bridges the gap between innovative research and clinical application, focusing on advancements in polymeric nanoparticles, lipid carriers, carbon nanotubes, and immunotherapy approaches. The book provides an in-depth analysis of current technologies and future directions in integrating nanocarriers into NHL management. Each chapter offers evidence-based insights and mechanisms of action, emphasizing the synergy between immunotherapy, precision medicine, and nanotechnology. This resource benefits its academic audience by equipping healthcare professionals with innovative strategies to improve treatment outcomes and inspiring researchers to explore novel therapeutic pathways. By fostering interdisciplinary collaboration among oncologists, pharmaceutical developers, and nanotechnology experts, the book ultimately guides future research to enhance patient care in the rapidly evolving field of non-Hodgkin’s lymphoma management.
1. Chapter 1 Introduction to non-Hodgkin’s disease and conventional therapies - p. 1 2. Chapter 2 Immune checkpoint inhibitors in the management of Non-Hodgkin’s Lymphoma: An emerging paradigm in reprogramming antitumor immunity - p. 33 3. Chapter 3 Exploring polymeric nanoparticles in Non-Hodgkin’s Lymphoma management - p. 67 4. Chapter 4 Magnetic nanoparticles in Non-Hodgkin’s Lymphoma therapy: Advancements and future directions - p. 87 5. Chapter 5 Leveraging nanostructured lipid carriers (NLCs) in Non-Hodgkin’s Lymphoma management - p. 113 6. Chapter 6 Breakthrough in antibody–drug conjugates for Non-Hodgkin Lymphoma management - p. 135 7. Chapter 7 Targeted Non-Hodgkin’s Lymphoma management with carbon nanotubes - p. 161 8. Chapter 8 Advancement in Non-Hodgkin’s Lymphoma management using exosomes - p. 187 9. Chapter 9 Immunological and molecular insights into vaccine-based and immunotherapeutic strategies for Non-Hodgkin’s Lymphoma - p. 205 10. Chapter 10 Immunotherapy and radioimmunotherapy approaches for Non-Hodgkin’s Lymphoma management - p. 227 11. Chapter 11 Innovative mRNA-based therapeutic strategies for Non-Hodgkin’s Lymphoma management - p. 265 12. Chapter 12 Monoclonal antibody and CAR T-cell therapy: A novel avenue in Non-Hodgkin’s Lymphoma management - p. 291 13. Chapter 13 Combination of nanocarrier with chemotherapy for Non-Hodgkin’s Lymphoma management - p. 305 14. Chapter 14 Patient care in Non-Hodgkin’s Lymphoma management - p. 329 15. Chapter 15 Regulatory challenges and approvals for nanocarrier-based therapies - p. 349 16. Index - p. 369
